Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 25;17(9):1451.
doi: 10.3390/nu17091451.

Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients

Affiliations
Review

Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients

Andrea Sechi et al. Nutrients. .

Abstract

Among the distressing side effects of cancer treatments, hair loss is one of the most disturbing for the quality of life and adherence to therapy in breast cancer patients. Many patients take nutritional supplements to prevent hair loss or enhance regrowth. Based on their mechanism and timing of use, nutritional supplements could be divided into safe, cautious, debated, and contraindicated categories. Non-contraindicated supplements generally include safe supplements like vitamin D, which is not known to interfere with cancer treatments. Those that are contraindicated include phytoestrogens and compounds affecting estrogen pathways because of the risk of stimulating tumor growth in cancers sensitive to estrogen. Antioxidants like tocotrienols and resveratrol are given judiciously because of potential interference with cancer therapies dependent on reactive oxygen species. Supplements debated, including nicotinamide, folate, and iron, pose a risk by promoting cellular proliferation or altering the tumor microenvironment. Biotin is nontoxic but interferes with blood test results and is thus difficult in cancer monitoring. Evidence regarding nutritional supplements' safety and efficacy in this context is conflicting. Management by an oncologist is required along with more studies to clearly establish the safety parameters and efficacy guidelines.

Keywords: breast cancer; chemotherapy-induced alopecia; hair loss; immunotherapy; safety profile; targeted therapy; telogen effluvium.

PubMed Disclaimer

Conflict of interest statement

D.P. and F.R. work for Giuliani SpA that covered the expenses of Open Access.

References

    1. Hanker A.B., Sudhan D.R., Arteaga C.L. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37:496–513. doi: 10.1016/j.ccell.2020.03.009. - DOI - PMC - PubMed
    1. International Agency for Research on Cancer (IARC) Global Cancer Observatory. [(accessed on 31 October 2024)]. Available online: https://gco.iarc.fr/
    1. Freites-Martinez A., Shapiro J., van den Hurk C., Goldfarb S., Jimenez J.J., Rossi A.M., Paus R., Lacouture M.E. Hair Disorders in Cancer Survivors. J. Am. Acad. Dermatol. 2019;80:1199–1213. doi: 10.1016/j.jaad.2018.03.056. - DOI - PMC - PubMed
    1. Baker R., Dell’Acqua G., Richards A., Thornton M.J. Nutraceuticals Known to Promote Hair Growth Do Not Interfere with the Inhibitory Action of Tamoxifen in MCF7, T47D and BT483 Breast Cancer Cell Lines. PLoS ONE. 2024;19:e0297080. doi: 10.1371/journal.pone.0297080. - DOI - PMC - PubMed
    1. Dell’Acqua G., Richards A., Thornton M.J. The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy. Nutrients. 2020;12:3537. doi: 10.3390/nu12113537. - DOI - PMC - PubMed

MeSH terms